- $16.13m
- $9.90m
- $28.51m
Brief: Bionano Announces Software Marketing Agreement With Revvity For Newborn Sequencing Research
Brief: Bionano Announces Three Publications Demonstrating OGM’s Utility for Cell and Gene Therapy
Bionano Genomics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Bionano Genomics Q1 Revenue USD 8.8 Million
Bionano Genomics Inc expected to post a loss of 64 cents a share - Earnings Preview
Brief: Bionano and Diagens Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis that Combines OGM and AI
Brief: Bionano Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Brief: Bionano Reports Fourth Quarter And Full-Year 2023 Results
Brief: Bionano Genomics Q4 Revenue USD 10.7 Million Vs. IBES Estimate USD 10.6 Million
Bionano Genomics Inc expected to post a loss of 87 cents a share - Earnings Preview
Brief: Bionano Announces Amendment To Debt Financing Arrangement
Brief: Bionano Announces Publication Of Interim Readout From Second Phase Of Clinical Trial Analyzing Optical Genome Mapping As Standard Of Care (Soc) For Prenatal Testing
Brief: Bionano Announces Peer-Reviewed Publication From Its Clinical Study Designed To Support OGM As Part Of Standard Of Care In Genetic Disease Testing
Brief: Bionano Reports Prelim Q4 And Full-Year 2023 Results
U.S. RESEARCH ROUNDUP-Biomarin Pharmaceutical, Cisco, Microsoft
Brief: Bionano Genomics Q3 Revenue USD 9.3 Million Vs. IBES Estimate USD 9.08 Million
Bionano Genomics Inc expected to post a loss of 97 cents a share - Earnings Preview
Brief: Bionano Announces Third Oem Partner Has Received China Nmpa Approval For Dna Isolation Products For Ivd Use Of Ogm
Brief: Bionano Announces 2nd Oem Partner Has Received China Nmpa Approval For Dna Extraction And Labeling Products For Ivd Use Of Ogm In Reproductive Health